Pathological changes in multiple organs of rats with severe acute pancreatitis treated by baicalin and octreotide.
BACKGROUND
Severe acute pancreatitis (SAP) features fatal pathogenetic conditions and high mortality rate. The study of SAP complicated with multiple organ injuries is of important significance. In this study, we explored the protective effect of baicalin on multiple organs of SAP rats and compared it with that of octreotide through light and electron microscopic observations of the pathological changes.


METHODS
The improved Aho method was used to prepare SAP rat models. These rats were then randomly divided into a sham-operated group (n=45), a model control group (n=45), baicalin-treated group (n=45) and octreotide-treated group (n=45). Based on the difference in time points after operation, these groups were subdivided into 3, 6 and 12 hour subgroups (n=15). At the corresponding time point after operation, the mortality rate of rats was recorded, and then the rats were humanely killed to take samples of multiple organs that were subsequently examined for pathological changes under light and electron microscopy.


RESULTS
At 12 hours after operation, the mortality rate of rats in the baicalin- and octreotide-treated groups was lower than that in the model control group (P<0.05). Compared to the model control group, the pathological changes and pathological scores in the baicalin- and octreotide-treated groups were mitigated and relieved to varying degrees. The pathological changes under electron microscopy were also improved.


CONCLUSIONS
Both baicalin and octreotide show good protective effects on multiple organs of SAP rats. Baicalin as a new drug has good prospects in the treatment of SAP.
Zhang
Xi-Ping
XP
Department of General Surgery, Hangzhou First People's Hospital, Hangzhou 310006, China.
Tian
Hua
H
Wu
Di-Jiong
DJ
Feng
Guang-Hua
GH
Chen
Li
L
Zhang
Jie
J
Xu
Ru-Jun
RJ
Cai
Yang
Y
Ju
Tong-Fa
TF
Xie
Qi
Q
D000208:Acute Disease; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology; D005419:Flavonoids / Q000494:pharmacology*; D005765:Gastrointestinal Agents / Q000494:pharmacology; D007413:Intestinal Mucosa / Q000473:pathology; D007668:Kidney / Q000473:pathology; D008099:Liver / Q000473:pathology; D008168:Lung / Q000473:pathology; D008198:Lymph Nodes / Q000473:pathology; D008297:Male; D008516:Medicine, Chinese Traditional / Q000379:methods; D009102:Multiple Organ Failure / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology*; D015282:Octreotide / Q000494:pharmacology*; D010179:Pancreas / Q000473:pathology; D010195:Pancreatitis / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012720:Severity of Illness Index; D013154:Spleen / Q000473:pathology
D000894:Anti-Inflammatory Agents, Non-Steroidal; D005419:Flavonoids; D005765:Gastrointestinal Agents; C038044:baicalin; D015282:Octreotide